Literature DB >> 25636129

Plasma for fractionation in a public setting: cost analysis from the perspective of the third-party payer.

Mario Eandi1, Giorgio Gandini2, Massimiliano Povero3, Orietta Zaniolo3, Lorenzo Pradelli3, Giuseppe Aprili2.   

Abstract

BACKGROUND: In Italy, within the legal mandate to pursue national self-sufficiency of plasma-derived medical products, the Regions are starting to organise trade to offset imbalances between need and availability. It is, therefore, necessary to determine the full cost to the Regions of plasma collection and handling. Here we report an analysis of plasma production costs in the Department of Transfusion Medicine of Verona Province, Veneto Region.
MATERIALS AND METHODS: Plasma is obtained from voluntary, non-remunerated donors from either whole blood or apheresis donation, and in Verona it is collected, validated and distributed only in Regional Health Service facilities, and then delivered to industry for processing. The amounts and costs of materials and activities needed to collect, produce, validate and distribute plasma were obtained from the Department of Transfusion Medicine. Attributable overhead expenses were assumed at 15% of direct costs. When plasma was collected as part of whole blood or from multi-component apheresis, joint costs (the costs of the common manufacturing process before the separation) were allocated to the plasma based on the tariff for single components, taken as proxy of the willingness to pay for them. In an alternative scenario plasma recovered from whole blood donations was considered a by-product.
RESULTS: The estimated full cost of each valid unit of plasma derived from whole blood, multi-component apheresis, and plasma-apheresis was about € 30, € 73 and € 170, respectively. The estimated total cost per litre of plasma was € 113 for collection from whole blood and € 276 for collection from apheresis. When plasma recovered from whole blood donations was considered a by-product, its cost per litre was estimated to be € 26. DISCUSSION: Our results suggest that the Italian donor-based system, in addition to its ethical and social values, can supply plasma at an affordable cost, comparable (albeit slightly higher) with costs in other recent analyses.

Entities:  

Mesh:

Year:  2015        PMID: 25636129      PMCID: PMC4317088          DOI: 10.2450/2014.0066-14

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


  2 in total

Review 1.  Recommendations for the transfusion of plasma and platelets.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

2.  Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal product manufacturing.

Authors:  Giuliano Grazzini; Anna Ceccarelli; Deanna Calteri; Liviana Catalano; Gabriele Calizzani; Americo Cicchetti
Journal:  Blood Transfus       Date:  2013-09       Impact factor: 3.443

  2 in total
  2 in total

1.  Cost-utility and budget impact of methylene blue-treated plasma compared to quarantine plasma.

Authors:  Joseph B Babigumira; Solomon J Lubinga; Emma Castro; Brian Custer
Journal:  Blood Transfus       Date:  2016-11-16       Impact factor: 3.443

2.  Trends in Plasma Toll Fractionation for Self Sufficiency of Plasma-Derived Medicinal Products in Italy.

Authors:  Vincenzo De Angelis; Antonio Breda
Journal:  Transfus Med Hemother       Date:  2019-02-05       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.